Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Meanwhile AKRO.....a 2B$ company

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Oct 07, 2022 1:08pm

118 Views

Post# 35012654

RE:RE:RE:RE:Meanwhile AKRO.....a 2B$ company

I will say it again, you cannot talk about having the key without knowing if there is a lock that allows to open a door on the cancer cells you are trying to kill. In other words, they will need to adress the reality of sortilin overexpression related to any efficacy sign. We won't have any proof of concept without data about that critical aspect.